Resumen
La enfermedad de Pompe (EP) es debida a la deficiencia de la enzima lisosomal maltasa ácida o alfa glucosidasa ácida (AGA) y se manifiesta clínicamente como una miopatía. La cantidad y calidad de la enzima determinan la variedad de presentación. A continuación se presentan las formas de debut, características clínicas, hallazgos de laboratorio y evolución de dos casos evaluados con EP.
Citas
VAN DER PLOEG AT, REUSER AJ. Pompe's disease. Lancet 2008; 372: 1342-53.
VAN DEN HOUT HM, HOP W, VAN DIGGELEN OP, ET AL. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics 2003;112:332-40
POMPE JC. Over idiopatische hypertrophie van het hart. Ned Tijdschr Geneeskd 1932; 76: 304.
HERS HG. Alpha-glucosidase deficiency in generalized glycogen-storage disease. (Pompes disease). Biochem J 1963; 86: 11.
CHEN YT, AMALFITANO A. Towards a molecular therapy for glycogen storage disease type II (Pompe disease). Mol Med Today 2000; 6:245-51.
HIRSCHHORN R, REUSER AJJ. Glycogen storage disease type II: acid a-glucosidase (acid maltase) deficiency. In: Scriver CK, Beaudet AL, Sly WS, et al., eds. The metabolic & molecular bases of inherited disease. 8th ed. Vol. 3. New York: McGraw-Hill, 2001:3389-420.
REUSER AJJ, KROOS MA, HERMANS MMP, ET AL. Glycogenosis type II (acid maltase deficiency). Muscle Nerve 1995; 3:S61-S69.
AUSEMS MGEM, TEN BERG K, KROOS MA, ET AL. Glycogen storage disease type II: birth prevalence agrees with predicted genotype frequency. Community Genet 1999; 2:91-96.
AUSEMS MGEM, VERBIEST J, HERMANS MMP, ET AL. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counseling. Eur J Human Genet 1999; 7:713716.
CHIEN YH, CHIANG SC, ZHANG XK, KEUTZER J, LEE NC, HUANG AC, ET AL. Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program. Pediatrics 2008; 122(1): e39-45.
ENGEL AG, GOMEZ MR, SEYBOLD ME, LAMBERT EH. The spectrum and diagnosis of acid malt-ase deficiency. Neurology 1973; 23: 95.
SLONIM AE, BULONE L, RITZ S, ET AL. Identification of two subtypes of infantile acid maltase deficiency. J Pediatr 2000; 137:283-285.
REUSER AJJ, KROOS M, WILLEMSEN R, ET AL. Clinical diversity in glycogenosis type II: biosynthesis and in situ localization of acid alpha-glucosidase in mutant fibroblasts. J Clin Invest 1987; 79:1689-1699.
MELLIES U, LOFASO F. Pompe disease: a neu-romuscular disease with respiratory muscle involvement. Respir Med 2009; 103(4): 477-84.
ULRICH K, VON BASSEWITZ D, SHIN J, KORINTHENBERG R, SEWELL S, VON FIGURA K. Lysosomal glycogen storage disease without deficiency of alpha-glucosidase. Prog Clin Biol Res 1989; 306: 163.
LOTZ BP. Metabolic myopathies. In: Brown WF, et al, eds. Neuromuscular Function and Disease: Basic, Clinical, and Electrodiagnostic Aspects. Vol. 2. Philadelphia: WB. Saunders Company; 2002:14431445.
LENDERS MB, MARTIN JJ, DE BARSY T, CEYTERICK C, MARCHAU M. Acid maltase deficiency in adults. Acta Neurol Belg 1986; 86: 152.
ENGEL AG. Acid maltase deficiency in adults: studies in four cases of a syndrome which may mimic muscular dystrophy or other myopathies. Brain 1970; 93: 599-616.
MELLIES U, RAGETTE R, SCHWAKE C, ET AL. Sleep-disordered breathing and respiratory failure in acid maltase deficiency. Neurology 2001; 57: 12901295.
HAGEMANS ML, WINKEL LP, VAN DOORN PA, ET AL. Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. Brain 2005; 128: 671-7.
LAFORET P, NICOLINO M, EYMARD PB, ET AL. Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation. Neurology 2000; 55: 1122-8.
LYNCH CM, JOHNSON J, VACCARO C, ET AL. High-resolution light microscopy (HRLM) and digital analysis of Pompe disease pathology. JHistochem Cyto-chem 2005; 53: 63-73.
CHAMOLES NA, NIIZAWA G, BLANCO M, ET AL. Glycogen storage disease type II: enzymatic screening in dried blood spots on ilter paper. Clin Chim Acta 2004; 347: 97-102.
ROZAKLIS T, RAMSAY SL, WHITFIELD PD, ET AL. Determination of oligosaccharides in Pompe disease by electrospray ionization tandem mass spectrometry. Clin Chem 2002; 48: 131-139.
KISHNANI PS, CORZO D, LESLIE ND, ET AL. Early treatment with alglucosidase alfa prolongs long-term survival of infants with Pompe disease. Pediatr Res 2009; 66: 329-55.
NICOLINO M, BYRNE B, WRAITH JE, ET AL. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med 2009; 11: 210-9.
WINKEL LP, VAN DEN HOUT JM, KAMPHOVEN JH, ET AL. Enzyme replacement therapy in late-onset Pompe's disease: a threeyear follow-up. Ann Neurol 2004; 55: 495-502.
MELLIES U, STEHLING F, DOHNA-SCHWAKE C, RAGETTE R, TESCHLER H, VOIT T. Respiratory failure in Pompe disease: treatment with noninvasive ventilation. NEUROLOGY 2005; 64: 1465-7.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.